Literature DB >> 12959626

The incorporation of potential confounding variables in Markov models.

Mark J C Nuijten1, Frans Rutten.   

Abstract

OBJECTIVE: To improve the quality of the methods used in Markov modelling studies by increasing the external validity by means of the incorporation of confounding variables. STUDY
DESIGN: The concepts were illustrated using a hypothetical Markov model for Parkinson's disease.
METHODS: The methodology consisted of incorporation of an extra explanatory variable in the Markov health states by means of health state-specific relationships between this explanatory variable and costs as well as time-dependent values of the extra explanatory variable. In addition, we determined the relevance of the incorporation of an extra explanatory variable by means of various sensitivity analyses.
RESULTS: The results showed that the outcomes of a health economic model may be severely biased, when a confounding effect of an extra explanatory variable is not taken into account. Hence the external validity of Markov models may be limited, and consequently the results of the model are not an accurate reflection of reality.
CONCLUSION: This study proves the need for the incorporation of all relevant explanatory variables in a health economic model.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12959626     DOI: 10.2165/00019053-200321130-00003

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  10 in total

1.  Bridging decision analytic modelling with a cross-sectional study. Application to Parkinson's disease.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  2000-03       Impact factor: 4.981

2.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

3.  Applications of modelling studies.

Authors:  M J Nuijten; J Starzewski
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

Review 4.  The selection of data sources for use in modelling studies.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

5.  Current trends in the use of pharmacoeconomics and outcomes research in europe.

Authors:  M Drummond; D Dubois; L Garattini; B Horisberger; B Jönsson; I S Kristiansen; C Le Pen; C G Pinto; P B Poulsen; J Rovira; F Rutten; M G von der Schulenburg; H Sintonen
Journal:  Value Health       Date:  1999 Sep-Oct       Impact factor: 5.725

6.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046

7.  Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.

Authors:  U K Rinne; F Bracco; C Chouza; E Dupont; O Gershanik; J F Marti Masso; J L Montastruc; C D Marsden
Journal:  Drugs       Date:  1998       Impact factor: 9.546

8.  Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.

Authors:  C LePen; S Wait; F Moutard-Martin; M Dujardin; M Ziégler
Journal:  Pharmacoeconomics       Date:  1999-07       Impact factor: 4.981

9.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

10.  Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.

Authors:  P Davey; N Rajan; M Lees; M Aristides
Journal:  Value Health       Date:  2001 Jul-Aug       Impact factor: 5.725

  10 in total
  3 in total

Review 1.  Modelling the cost effectiveness of treatments for Parkinson's disease: a methodological review.

Authors:  Judith Dams; Bernhard Bornschein; Jens Peter Reese; Annette Conrads-Frank; Wolfgang H Oertel; Uwe Siebert; Richard Dodel
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

2.  Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].

Authors:  Mark Nuijten; Daniela P Roggeri; Alessandro Roggeri; Paolo Novelli; Thomas S Marshall
Journal:  Clin Drug Investig       Date:  2015-04       Impact factor: 2.859

3.  Incorporation of uncertainty in health economic modelling studies.

Authors:  Mark Nuijten
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.